推薦產品
3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyrazole 2-(chloromethyl)-3-methylpyridinehydrochloride 1-(2-bromo-4-methylphenyl)ethanone 3-chloroisoquinoline-4-carbonitrile 5,8-dichloropyrido[3,2-d]pyridazine 2-bromomalononitrile 2-(4-(bromomethyl)phenyl)benzo[d]thiazole 1-(bromomethyl)-3-methoxy-2-nitrobenzene 6-bromo-1H-[1,2,3]triazolo[4,5-b]pyridine 4-iodo-2-((trimethylsilyloxy)methyl)thiazole 6-iodoimidazo[1,2-a]pyridine-3-carbonitrile 2-(4-chlorophenyl)-2-morpholinoacetonitrile 4-chloro-7H-pyrrolo[2,3-d]pyrimidine 4-chloroisothiazole 5-bromo-6-chloro-1H-indole 7-chloro-3H-imidazo[4,5-b]pyridine ethyl3-(4-formylphenyl)propanoate 2,3-dibromobenzaldehyde 1-(5H-chromeno[2,3-b]pyridin-7-yl)ethanone 5H-chromeno[2,3-b]pyridin-5-one 3-chloroisoquinoline-4-carbaldehyde (E)-2-(3-oxoprop-1-enyl)benzaldehyde methyl4-formyl-3-nitrobenzoate 5,6-dimethoxy-2,2-dimethyl-2,3-dihydro-1H-inden-1-one 1-methylbicyclo[4.1.0]heptan-3-one 3-nitro-4-(trifluoromethoxy)benzaldehyde 2-hydroxyquinoline-6-carbaldehyde 2-nitro-3-(trifluoromethyl)benzaldehyde 1-(2-fluoro-4-methoxyphenyl)propan-2-one tert-butyl3-fluoro-4-oxopiperidine-1-carboxylate tert-butyl3-oxopropylcarbamate 2,2-dimethylcyclohexanone 9H-carbazole-3-carbaldehyde N,N-dimethyl-2-oxoacetamide 2-methylpent-4-yn-2-ol 3-tert-butyl-4-hydroxybenzonitrile 4-bromo-2-tert-butylphenol 1,3-dibutoxypropan-2-ol methyl4-hydroxyquinoline-6-carboxylate methyl3-cyano-4-hydroxybenzoate 4-chloro-6-methoxyquinolin-7-ol 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-ol 2-(2-aminothiazol-5-yl)ethanolhydrochloride (R)-ethyl2-chloropropanoate (S)-4-amino-5-(4,4-dimethylcyclohexylamino)-5-oxopentanoicacid (1s,4s)-4-hydroxycyclohexanecarboxylicacid (S)-2-(tetrahydrofuran-3-yloxy)aceticacid (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol (R)-4-(hydroxymethyl)oxazolidin-2-one (S)-4-(hydroxymethyl)oxazolidin-2-one 化工資訊 中國宏橋發(fā)布公告，于2020年11月25日，宏橋控股、公司與配售代理訂立配售及認購協(xié)議。根據配售及認購協(xié)議，配售代理有條件同意按盡力基準以配售價6.30港元向獨立承配人配售宏橋控股持有的配售股份3.08億股，且宏橋控股有條件同意按認購價(與配售價相同)向宏橋控股配發(fā)及發(fā)行認購股份，配售價每股6.30港元，較11月24日聯(lián)交所所報收市價每股7.32港元折讓約13.93%。
假設根據認購事項由公司配發(fā)及發(fā)行及由宏橋控股認購3.08億股股份，公司自認購事項收取的所得款項凈額將約為19億港元。公司擬將所得款項凈額用作發(fā)展再生鋁及輕量化材料生產線及補充集團的日常營運資金。
公告稱，鑒于當前資本市場狀況，董事會認為配售事項及認購事項乃一良機，可供公司進一步籌集資本，同時亦擴大其股東及資本基礎。
認購事項所得款項凈額，于扣減相關開支后約為19億港元，將作以下用途：50%用作發(fā)展再生鋁及輕量化材料生產線為進一步擴大集團的業(yè)務及提高其研發(fā)能力，公司將利用約50%的所得款項凈額以發(fā)展再生鋁及輕量化材料生產線。50%用作補充集團的日常營運資金為保證公司順利運作及減少融資成本，公司將利用約50%的所得款項凈額(約9.5億港元)補充集團的日常營運資金(包括采購原材料、研發(fā)開支及稅項)。
